Search research articles
Contact Us
Filters
Showing results (121-130 of 138) with videos related to
Page
of 14
Sort By:
Psoriasis (Auckland, N.Z.)
|
September 22, 2025
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study
Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Clinical and Experimental Dermatology
|
January 13, 2026
Long-Term Effectiveness of Bimekizumab in Plaque Psoriasis: Two-Year Drug Survival from a Real-Life Multicenter Italian Study
Eleonora De Luca, Annunziata Dattola, Fabio Artosi, et al.
The Journal of Dermatological Treatment
|
January 23, 2026
Risankizumab super responders in moderate-to-severe psoriasis: prevalence, predictors, and long-term maintenance in a multicenter, international, real-world cohort
Diego Orsini, Luca Potestio, Matteo Megna, et al.
Archives of Dermatological Research
|
May 23, 2025
Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study-IL AD (Italian Landscape Atopic Dermatitis)
Luca Potestio, Cataldo Patruno, Alessandra Narcisi, et al.
The Journal of Dermatological Treatment
|
September 24, 2025
Psoriasis severity, comorbidity burden, and biologic therapy: a multicenter observational study using the Charlson Comorbidity Index
Nicoletta Bernardini, Annunziata Dattola, Giuseppe Paolo Antonio Gemma, et al.
Dermatology and Therapy
|
June 9, 2026
Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study
Luciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, et al.
Dermatology and Therapy
|
February 16, 2026
Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab-IL PSO (Italian Landscape Psoriasis)
Emanuele Trovato, Alessandra Cartocci, Francesca Gaiani, et al.
Dermatology and Therapy
|
March 17, 2026
Short-Term Effectiveness and Safety of Deucravacitinib in Psoriasis: A Multicenter Real-World Study with Scalp-Specific Outcomes-IL PSO (Italian Landscape Psoriasis)
Luciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, et al.
Dermatology and Therapy
|
July 3, 2025
Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA-IL PSO (Italian Landscape Psoriasis)
Mario Valenti, Luciano Ibba, Sara Di Giulio, et al.
Clinical and Experimental Dermatology
|
November 1, 2025
Cumulative clinical benefits of biologic treatments in patients with moderate-to-severe psoriasis: an Italian real-life experience - IL PSO (Italian Landscape Psoriasis)
Diego Orsini, Luca Potestio, Maria Concetta Fargnoli, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 138) with videos related to
Sort By:
Page
of 14
Psoriasis (Auckland, N.Z.)
|
September 22, 2025
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study
Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Clinical and Experimental Dermatology
|
January 13, 2026
Long-Term Effectiveness of Bimekizumab in Plaque Psoriasis: Two-Year Drug Survival from a Real-Life Multicenter Italian Study
Eleonora De Luca, Annunziata Dattola, Fabio Artosi, et al.
The Journal of Dermatological Treatment
|
January 23, 2026
Risankizumab super responders in moderate-to-severe psoriasis: prevalence, predictors, and long-term maintenance in a multicenter, international, real-world cohort
Diego Orsini, Luca Potestio, Matteo Megna, et al.
Archives of Dermatological Research
|
May 23, 2025
Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study-IL AD (Italian Landscape Atopic Dermatitis)
Luca Potestio, Cataldo Patruno, Alessandra Narcisi, et al.
The Journal of Dermatological Treatment
|
September 24, 2025
Psoriasis severity, comorbidity burden, and biologic therapy: a multicenter observational study using the Charlson Comorbidity Index
Nicoletta Bernardini, Annunziata Dattola, Giuseppe Paolo Antonio Gemma, et al.
Dermatology and Therapy
|
June 9, 2026
Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study
Luciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, et al.
Dermatology and Therapy
|
February 16, 2026
Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab-IL PSO (Italian Landscape Psoriasis)
Emanuele Trovato, Alessandra Cartocci, Francesca Gaiani, et al.
Dermatology and Therapy
|
March 17, 2026
Short-Term Effectiveness and Safety of Deucravacitinib in Psoriasis: A Multicenter Real-World Study with Scalp-Specific Outcomes-IL PSO (Italian Landscape Psoriasis)
Luciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, et al.
Dermatology and Therapy
|
July 3, 2025
Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA-IL PSO (Italian Landscape Psoriasis)
Mario Valenti, Luciano Ibba, Sara Di Giulio, et al.
Clinical and Experimental Dermatology
|
November 1, 2025
Cumulative clinical benefits of biologic treatments in patients with moderate-to-severe psoriasis: an Italian real-life experience - IL PSO (Italian Landscape Psoriasis)
Diego Orsini, Luca Potestio, Maria Concetta Fargnoli, et al.
Page
of 14